HRTS icon

Tema ETF Trust Tema Obesity & Cardiometabolic ETF

27.69 USD
+0.28
1.02%
At close Apr 17, 4:00 PM EDT
1 day
1.02%
5 days
2.98%
1 month
-8.34%
3 months
-3.52%
6 months
-19.32%
Year to date
-5.11%
1 year
-11.31%
5 years
3.98%
10 years
3.98%
0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

5.25% more ownership

Funds ownership: 21.05% [Q3] → 26.3% (+5.25%) [Q4]

5% more funds holding

Funds holding: 21 [Q3] → 22 (+1) [Q4]

0% more capital invested

Capital invested by funds: $17.9M [Q3] → $17.9M (+$23.1K) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for HRTS.

Financial journalist opinion

Positive
ETF Trends
3 months ago
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs
For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance to consider the investment opportunity in weight loss as a theme.
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs
Positive
ETF Trends
3 months ago
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends
2024 was an amazing year for investment performance, with the broad market S&P 500 TR Index up over 28%. There were also some serious ETF milestones achieved this year.
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends
Positive
ETF Trends
4 months ago
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.
Disruptive Theme of the Week – Breakthroughs in Medicine
Positive
ETF Trends
5 months ago
Disruptive Theme of the Week: Happy Post-Election Themes
With the completion of a close presidential election, roughly half of us are likely disappointed regardless of the winner. To counter the post-election blues, I identified some “happy” ETF themes to consider for investment.
Disruptive Theme of the Week: Happy Post-Election Themes
Positive
Zacks Investment Research
6 months ago
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
Positive
Zacks Investment Research
7 months ago
Tap the Weight-Loss Drug Market With These ETFs
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
Tap the Weight-Loss Drug Market With These ETFs
Neutral
ETF Trends
8 months ago
Disruptive Theme of the Week: Playing Defense
When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.
Disruptive Theme of the Week: Playing Defense
Positive
Invezz
8 months ago
How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)
The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.
How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)
Positive
Seeking Alpha
8 months ago
HRTS: Generating Alpha In Obesity Treatment
The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth companies, and start-ups with promising technology. An interview with the PM increased my understanding and confidence in the portfolio construction and strategy.
HRTS: Generating Alpha In Obesity Treatment
Positive
Zacks Investment Research
8 months ago
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
Charts implemented using Lightweight Charts™